$35.$ You have been managing a program to run the clinical trials for a new class of drugs that will

forever eliminate prickly heat in the subtropics. Partway through the trials, you discovered

that a competitor had already achieved regulatory approval to begin manufacturing and

selling an identical class of drugs that will be sold at half the cost of the drug that you are

developing. You met with your Governance Board to discuss the situation. The next step is

to$$

a$.$ Prepare a program closure recommendation

b$.$ Conduct an audit

c$.$ Prepare a performance report

d$.$ Terminate the program